Press Release
Birkerød, 3 October 2018
ViroGates A/S (Nasdaq First North Denmark: VIRO), who delivers blood test systems, primarily for emergency departments in hospitals, today announces that data from a study comprising 17,312 patients admitted at the Acute Medical Unit at Copenhagen University Hospital Amager and Hvidovre, Denmark has been published in the highly accredited medical journal Critical Care Medicine. The study analyzed the effect of measuring suPAR (using suPARnostic® ELISA products) compared to using a conventional triage/risk stratification system (The NEWS) that is used in the emergency departments and other acute medical units internationally.
The study concluded that using suPAR in combination with NEWS significantly improved risk prediction of both low- and high-risk acute medical patients. The study concluded that using suPAR in combination with NEWS could potentially lead to clinical interventions among acute medical patients otherwise not considered urgent or at risk, thereby ultimately saving lives. suPAR was a stronger predictor of mortality in patients without clinical signs of risk of deterioration. Patients with low NEWS but high suPAR levels had mortality risks comparable to that of patients with higher NEWS. suPAR and NEWS were both strongly associated with risk of in-hospital-, 30-day-, and 90-day mortality in acute medical patients. The suPAR level increased with increasing NEWS, and high suPAR independently predicted risk of mortality across NEWS scores thereby adding prognostic value to the NEWS.
CEO Jakob Knudsen, says in a comment: ”We are happy to see the publication of this extensive clinical work that has been conducted at Copenhagen University Hospital Amager and Hvidovre. The study confirms the ability of suPARnostic® to aid in the risk stratification process among patients that are admitted to the acute medical departments of the hospital. We consider the study results important for the clinical use of suPARnostic® since it demonstrates that improved risk stratification can be obtained by escalating patients with high suPAR values to receive more urgent care. Also, the study results indicate that patients with low suPAR can more safely be discharged early from the hospital.”
About the NEWS and suPAR study: The study was an observational study carried out at the Copenhagen University Hospital Amager Hvidovre from 18 November 2013 to 30 September 2015. The study included Acute Medical Unit patients with a NEWS and suPAR result. In total the study included 17,312 patients of which 16,244 patients had a NEWS score recorded. The study was registered and approved with the Danish Health and Medicines Authority (reference 3-3013-1061/2) and the Danish Data Protection Agency (reference HVH-2014-018, 02767). The publication can be obtained as a free access publication at https://journals.lww.com/ccmjournal/Abstract/onlinefirst/Combining_National_Early_Warning_Score_With.96134.aspx
For further information contact:
CEO Jakob Knudsen
Tel. (+45) 2113 1336, Email: jk@virogates.com
ViroGates A/S
CVR-nr. 25734033, Blokken 45, DK-340 Birkerød
www.virogates.com
Certified Advisor
Västra Hamnen Corporate Finance
Per Lönn
Tel. (+46) 40 200 250, Email: per.lonn@vhcorp.se
About ViroGates
ViroGates is an international Medtech company headquartered in Denmark. ViroGates develops and sells prognostic products to the healthcare sector. The products are used in hospital emergency services, in particular to make a clinical decision on hospitalization or discharge of emergency patients, which can lead to better clinical decisions, faster discharge and optimization of healthcare resources. The products can also be used for the prognosis of lifestyle-related diseases such as cardiovascular disease, type 2 diabetes, cancer, etc. The ViroGates test suPARnostic® measures the suPAR (Soluble urokinase Plasminogen Activator Receptor) protein in the bloodstream, and with the suPARnostic® Quick Triage and TurbiLatex test, hospital staff will get answers in just 20 minutes. The prognostic value of suPARnostic® is validated by more than 500 clinical trials and studies which included more than 300,000 blood samples.
Attachment
